Fig. 2From: Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United StatesSchematic of threshold analysis demonstrating the price at which pirfenidone and nintedanib are cost-effective treatment strategies compared to symptom managementBack to article page